Ultra-Short-Course Antibiotics for Suspected Pneumonia With Preserved Oxygenation.
antibiotic stewardship
oxygenation
pneumonia
quality improvement
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 02 2023
08 02 2023
Historique:
received:
13
06
2022
pmc-release:
08
02
2024
pubmed:
28
7
2022
medline:
11
2
2023
entrez:
27
7
2022
Statut:
ppublish
Résumé
Suspected pneumonia is the most common indication for antibiotics in hospitalized patients but is frequently overdiagnosed. We explored whether normal oxygenation could be used as an indicator to support early discontinuation of antibiotics. We retrospectively identified all patients started on antibiotics for pneumonia in 4 hospitals with oxygen saturations ≥95% on ambient air, May 2017-February 2021. We propensity-matched patients treated 1-2 days vs 5-8 days and compared hospital mortality and time to discharge using subdistribution hazard ratios (SHRs). Secondary outcomes included readmissions, 30-day mortality, Clostridioides difficile infections, hospital-free days, and antibiotic-free days. Among 39 752 patients treated for possible pneumonia, 10 012 had median oxygen saturations ≥95% without supplemental oxygen. Of these, 2871 were treated 1-2 days and 2891 for 5-8 days; 4478 patients were propensity-matched. Patients treated 1-2 vs 5-8 days had similar hospital mortality (2.1% vs 2.8%; SHR, 0.75 [95% confidence interval {CI}, .51-1.09]) but less time to discharge (6.1 vs 6.6 days; SHR, 1.13 [95% CI, 1.07-1.19]) and more 30-day hospital-free days (23.1 vs 22.7; mean difference, 0.44 [95% CI, .09-.78]). There were no significant differences in 30-day readmissions (16.0% vs 15.8%; odds ratio [OR], 1.01 [95% CI, .86-1.19]), 30-day mortality (4.6% vs 5.1%; OR, 0.91 [95% CI, .69-1.19]), or 90-day C. difficile infections (1.3% vs 0.8%; OR, 1.67 [95% CI, .94-2.99]). One-quarter of hospitalized patients treated for pneumonia had oxygenation saturations ≥95% on ambient air. Outcomes were similar with 1-2 vs 5-8 days of antibiotics. Normal oxygenation levels may help identify candidates for early antibiotic discontinuation. Prospective trials are warranted.
Sections du résumé
BACKGROUND
Suspected pneumonia is the most common indication for antibiotics in hospitalized patients but is frequently overdiagnosed. We explored whether normal oxygenation could be used as an indicator to support early discontinuation of antibiotics.
METHODS
We retrospectively identified all patients started on antibiotics for pneumonia in 4 hospitals with oxygen saturations ≥95% on ambient air, May 2017-February 2021. We propensity-matched patients treated 1-2 days vs 5-8 days and compared hospital mortality and time to discharge using subdistribution hazard ratios (SHRs). Secondary outcomes included readmissions, 30-day mortality, Clostridioides difficile infections, hospital-free days, and antibiotic-free days.
RESULTS
Among 39 752 patients treated for possible pneumonia, 10 012 had median oxygen saturations ≥95% without supplemental oxygen. Of these, 2871 were treated 1-2 days and 2891 for 5-8 days; 4478 patients were propensity-matched. Patients treated 1-2 vs 5-8 days had similar hospital mortality (2.1% vs 2.8%; SHR, 0.75 [95% confidence interval {CI}, .51-1.09]) but less time to discharge (6.1 vs 6.6 days; SHR, 1.13 [95% CI, 1.07-1.19]) and more 30-day hospital-free days (23.1 vs 22.7; mean difference, 0.44 [95% CI, .09-.78]). There were no significant differences in 30-day readmissions (16.0% vs 15.8%; odds ratio [OR], 1.01 [95% CI, .86-1.19]), 30-day mortality (4.6% vs 5.1%; OR, 0.91 [95% CI, .69-1.19]), or 90-day C. difficile infections (1.3% vs 0.8%; OR, 1.67 [95% CI, .94-2.99]).
CONCLUSIONS
One-quarter of hospitalized patients treated for pneumonia had oxygenation saturations ≥95% on ambient air. Outcomes were similar with 1-2 vs 5-8 days of antibiotics. Normal oxygenation levels may help identify candidates for early antibiotic discontinuation. Prospective trials are warranted.
Identifiants
pubmed: 35883250
pii: 6650366
doi: 10.1093/cid/ciac616
pmc: PMC10498383
mid: NIHMS1926597
doi:
Substances chimiques
Anti-Bacterial Agents
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1217-e1223Subventions
Organisme : NCEZID CDC HHS
ID : U54 CK000484
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. M. K. has received royalties from UpToDate for articles on pneumonia and has also received grants from the Agency for Healthcare Research and Quality. C. R. has received royalties from UpToDate for articles on procalcitonin; payments for consulting related to sepsis diagnostics from Cytovale; and payments from Pfizer for consulting related to Lyme disease surveillance. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Crit Care Med. 2013 Sep;41(9):2151-61
pubmed: 23760154
JAMA. 1997 Nov 5;278(17):1440-5
pubmed: 9356004
Intensive Care Med. 2020 Jun;46(6):1170-1179
pubmed: 32306086
Chest. 2020 Dec;158(6):2370-2380
pubmed: 32615191
J Clin Virol. 2017 Jun;91:52-57
pubmed: 28494435
JAMA Netw Open. 2020 Jul 1;3(7):e2010700
pubmed: 32678449
Am J Health Syst Pharm. 2020 Feb 7;77(4):282-287
pubmed: 31909417
JAMA. 2014 Oct 8;312(14):1438-46
pubmed: 25291579
Eur Respir Rev. 2016 Jun;25(140):178-88
pubmed: 27246595
Crit Care Med. 2002 Feb;30(2):368-75
pubmed: 11889312
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Histopathology. 2005 Dec;47(6):551-9
pubmed: 16324191
Stat Med. 2019 Feb 28;38(5):751-777
pubmed: 30347461
Crit Care Med. 2009 Aug;37(8):2360-8
pubmed: 19531951
Lancet Infect Dis. 2014 Dec;14(12):1220-7
pubmed: 25455989
Respir Med. 2017 Jan;122:76-80
pubmed: 27993295
BMJ. 2006 Jun 10;332(7554):1355
pubmed: 16763247
J Hosp Infect. 2018 Jul;99(3):312-317
pubmed: 29621601
J Crit Care. 2010 Mar;25(1):62-8
pubmed: 19592209
Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):505-11
pubmed: 10934078
Clin Infect Dis. 2021 May 18;72(10):1784-1792
pubmed: 32519751
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Med Care. 2018 Jul;56(7):626-633
pubmed: 29668648
MMWR Morb Mortal Wkly Rep. 2014 Mar 7;63(9):194-200
pubmed: 24598596
Lancet. 2021 Mar 27;397(10280):1195-1203
pubmed: 33773631
Am J Respir Crit Care Med. 2015 Oct 15;192(8):974-82
pubmed: 26168322
Eur Respir J. 2018 May 30;51(5):
pubmed: 29650558
J Chronic Dis. 1987;40(7):705-12
pubmed: 3110198
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Infect Control Hosp Epidemiol. 2014 Mar;35(3):278-84
pubmed: 24521594
Intensive Care Med. 2020 Jul;46(7):1394-1403
pubmed: 32468084
Clin Infect Dis. 2011 Feb 1;52(3):325-31
pubmed: 21217179
JAMA Netw Open. 2021 Mar 1;4(3):e212007
pubmed: 33734417